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Although colon carcinoma cells express Fas receptors, they are resistant to Fas-mediated apoptosis. Defects within the intracellular
Fas signal transduction may be responsible. We investigated whether the Fas-associated phosphatase-1 (FAP-1), an inhibitor of Fas
signal transduction, contributed to this resistance in colon carcinomas. In vivo, apoptosis of cancer cells was detected in situ using
terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling (TUNEL). FAP-1, FasR, and Fas ligand (FasL) were detected
using immunohistochemistry. In vitro, colon carcinoma cells were primarily cultured, and their sensitivity to Fas-mediated apoptosis
was evaluated by treatment with agonistic anti-FasR CH11 IgM monoclonal antibody in the presence or absence of synthetic Ac-SLV
(serine-leucine-valine) tripeptide. Fas-associated phosphatase-1 expression was detected in 20 out of 28 colon adenocarcinomas. In
vivo, a positive correlation between the percentage of apoptotic tumour cells and the number of FasL-positive tumour infiltrating
lymphocytes was observed in FAP-1 negative cancers, but not in FAP-1-positive ones. Primarily cultured colon cancer cells, which
were refractory to CH-11-induced apoptosis, had higher expression of FAP-1 on protein and mRNA levels than the sensitive group.
Resistance to Fas-mediated apoptosis in tumour cells could be abolished by Ac-SLV tripetides. Fas-associated phosphatase-1
expression protects colon cancer cells from Fas-mediated apoptosis, and blockade of FAP-1 and FasR interaction sensitises tumour
cells to Fas-dependent apoptosis.
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Despite the presence of tumour-specific cytotoxic T lymphocytes
(CTLs) and natural killer (NK) cells, the immune system fails to
contain colon cancers. These malignancies are able to escape
immune clearance, and are resistant to cytotoxic activities of host
immunonocytes (Halapi, 1998; Beatty and Paterson, 2000; Song
et al, 2001a). However, the exact mechanisms by which colon
cancer cells escape CTL or NK cell-mediated destruction remain
poorly understood.
The Fas–Fas ligand (FasL) interacting system has been
recognised as a major pathway for CTL- and NK cell-mediated
apoptotic cell death (Ka ¨gi et al, 1994; Lowin et al, 1994; Arase et al,
1995). When CTLs or NK cells recognise target cells, they become
activated and express FasL, which binds to Fas receptors on the
surface of the target cells and induce target cell apoptosis
(Leithauser et al, 1993; Suda et al, 1993; Suda and Nagata, 1994;
Nagata, 1997). Upon contact with crosslinking anti-Fas antibodies
or FasL, the Fas-bearing cells rapidly undergo apoptosis. Although
colon cancer cells abundantly express Fas receptors at mRNA and
protein level, they are insensitive to FasR-mediated apoptosis
(Leithauser et al, 1993; O’Connell et al, 1998; Grosch et al, 2001;
Vermijlen et al, 2001).
The resistance of most colon cancer cells to FasL-induced
apoptosis may explain their capability to escape immune cytolysis
(Tillman et al, 1998; von Reyher et al, 1998). However, the
molecular mechanisms of this process are still unknown. Some
authors suggest that the FasR resistance of colon cancer cells is
based on defects of intracellular Fas signal transduction (O’Connell
et al, 1998; Vermijlen et al, 2001).
Fas-associated phosphatase-1 (FAP-1) is a tyrosine phosphatase,
which intracellularly inhibits FasR-mediated apoptosis. By inter-
acting with the cytoplasmic death domain of Fas receptors, FAP-1
acts as a negative switch in the Fas pathway. Introduction of FAP-1
into Fas-sensitive cells blocks FasL-induced apoptosis (Ungefroren
et al, 2001). Furthermore, FAP-1 overexpression correlates with the
resistance of some human malignant cells to Fas-mediated
apoptosis, such as pancreatic cancer cells, hepatoblastoma cells,
leukaemia T cells and AIDS-associated Kaposi’s sarcoma cells (Lee
et al, 1999a).
In a multistep oral carcinogenesis model, the expression of
FAP-1 increased in parallel to the progression towards malignancy
(Itakura et al, 2000). On the other hand, spontaneous
downregulation of FAP-1 expression contributes to the excessive
apoptosis of haematopoietic cells in myelodysplastic syndromes
(Bernhard et al, 2001). Furthermore, interruption of the
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yconjugation between FasR and FAP-1 by a synthetic Serine-
Leucine-Valine (Ac-SLV) tripeptide abolished the resistance to
FasR-mediated apoptosis in human thymocytes (Song et al,
2001b). Thus, it is clear that FAP-1 plays an essential regulatory
role in Fas-mediated apoptosis. However, although colon cancers
have been found to express FAP-1, its contribution to Fas
resistance has not been determined.
Therefore, the present study examined the expression of FAP-1
in colon cancer cells, and investigated whether FAP-1 contributed
to the resistance of colon cancer against FasR-mediated apoptosis.
MATERIALS AND METHODS
Patients and tissue samples
Tissue samples of human colon adenocarcinomas from 28 patients
were collected, with informed consent, after surgical resections
performed at Sun-Yat-Sen University of Medical Science, Guangz-
hou, following a protocol approved by the University Teaching
Hospitals ethics committee. None of the patients had received
chemo-, radio-, or immuno-therapy before resection. Tumours
were well (n¼9), moderately (n¼11), and poorly (n¼8)
differentiated including three cases of mucinous adenocarcinomas.
Pathological staging followed the rules of the Dukes system, with
seven cases of Dukes A (T1N0M0: mucosa only), 12 cases of Dukes
B( T 2N0M0: into but not through the muscularis propria) and nine
cases of Dukes C (TnN1M0: locally positive nodes). None of the
cases was found to have metastases to distal organs. Tissue
samples were used in part for primary cell cultures. The rest was
snap frozen in liquid nitrogen and stored at  801C for
immunohistochemical staining.
Immunohistochemistry
A polyclonal antibody for Fas (C20; dilution 1/50), a polyclonal
antibody for FasL (N20; dilution 1/50), and a polyclonal antibody
for FAP-1 (C20; dilution 1/50) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). A monoclonal antibody for
leucocyte common antigen CD45 (clone 2B11þPD7/26; dilution 1/
70) for the identification of tumour infiltrating lymphocytes (TILs)
and a labelled streptavidin–biotin (LSAB) immunohistochemical
detection kit were obtained from Dako Corp. (Carpinteria, CA).
Acetone-fixed consecutive cryostat tissue sections (4mm) of
colon cancers were stained immunohistochemically with the above
antibodies according to the standard LSAB staining techniques.
Briefly, endogenous peroxidase activity was quenched by incuba-
tion with 3.0% hydrogen peroxide in methanol for 5min. Sections
were washed in phosphate-buffered saline (PBS) and blocked for
1h in a washing buffer containing 5% normal goat serum (Sigma
Chemical Co, St Louis, MO, USA). The primary antibody was
added for incubation overnight at 41C. After washing in PBS, the
sites of primary antibody binding were localised by sequential
incubation with biotinylated goat anti-rabbit antibody and then
streptavidin conjugated with horseradish peroxidase. After further
washing in PBS, diaminobenzidine (DAB; Dako Corp., Carpinteria,
CA, USA) was used as a chromogen and sections were lightly
counterstained with haematoxylin. As negative controls for Fas,
FasL, and FAP-1, the immunising peptide to which the antibodies
were raised (Dako Corp. Carpinteria, CA, USA) were added at
1mgml
 1 to the primary antibody as a direct, internal competitive
control. As a negative control for CD45, we used nonimmune
mouse serum instead of the CD45 monoclonal antibody.
Assessment of FasL-positive TILs
Tumour infiltrating lymphocytes were identified by CD45 staining
in consecutive sections, and those that were adjacent to tumour
nests were counted for positive immunohistochemical staining of
FasL under high-power microscopy ( 400, more than 30 fields
counted per section). The view fields for cell counting were chosen
according to a systematic random sampling method. FasL-positive
TILs were expressed as cells per field of view (c/FV).
Detection of in situ cell death by terminal
deoxynucleotidyltransferase-mediated dUTP nick-end
labelling (TUNEL)
Cell death was detected in situ in resected tissues by enzymatic
labelling of DNA strand breaks with a TUNEL assay (Boehringer
Mannheim GmbH, Mannheim, Germany) according to the
manufacturer’s instructions. Cryostat sections were treated with
proteinase K (20mgml
 1 in 10mM Tris/HCl, pH 7.6) for 30min.
After washing, peroxidase block was similar to that described
above. The samples were permeabilised (0.1% Triton X-100 in
0.1% sodium citrate 15min). For the labelling reaction, a TdT
buffer solution (composition: potassium cacodylate 100mmoll
 1;
cobalt chloride 2mmoll
 1; dithiothreitol 0.2mmoll
 1; pH 7.2)
containing 0.3Uml
 1 biotinylated dUTP was added to cover the
sections, incubated at 371C for 60min in a humidified chamber.
TdT was omitted from negative control slides. To localise cells
containing labelled DNA strand breaks, sections were washed and
incubated with peroxidase-labelled streptavidin for 30min, and
were finally stained with DAB solutions, followed by counter-
staining with haematoxylin. Approximately 1000 colon cancer cells
were counted under high-power microscopy ( 400) and the
percentage of TUNEL-positive tumour cells with apoptotic
morphology was calculated.
Primary cell culture of colon cancer
Cell suspensions derived from tumour samples were obtained by
enzymatic digestion with medium containing 0.1%. collagenase
type IA, 0.002% DNase type II and 0.05% protease type I (Sigma
Chemical Co, St Louis, MO, USA). Tumour cells were isolated by
adherence to plastic culture vessels for 36h in a 5% CO2 incubator
at 371C. Supernatants were discarded and tumour cells were
cultured in RPMI 1640 supplemented with 10% FCS in a
humidified 5% CO2 atmosphere. Assessment of tumour cells was
performed by light microscopy, electronic microscopy and
immunohistochemistry for keratin.
Assessment of anti-FasR mAb CH11-induced apoptosis
Sensitivity of primarily cultured colon cancer cells to Fas-mediated
apoptosis was determined by treatment with the agonistic anti-
FasR CH11 IgM monoclonal antibody (Kamiya Biomedical Co,
Thousand Oaks, CA, USA) at concentrations of 10, 100, 500, and
1000ngml
 1, or isotype control IgM (Kamiya) at a concentration
of 1000ngml
 1. In some experiments, cells were pretreated with
20mM of synthetic Ac-SLV tripeptide (Calbiochem-Novabiochem,
La Jolla, CA, USA), an inhibitor of FAP-1, for 12h, and were
subsequently incubated with anti-FasR CH11 MoAb.
After 24h of incubation, the number of apoptotic primarily
cultured colon cancer cells was determined by TUNEL assay
(Boehringer Mannheim GmbH) and flow cytometry. Briefly,
1 10
6 cells were washed in PBS and permeabilised with 0.1%
Triton X-100 in 0.1% sodium citrate solution on ice for 5min. Cells
were washed again and incubated for 60min at 371C in a labelling
TUNEL reaction mixture containing TdT reaction buffer (10.0ml),
Br-dUTP (8.0ml), dH2O (32.25ml), and TdT (0.75ml). The reaction
was then terminated by the addition of a rinse buffer. Cells were
washed before resuspension in 0.1ml of rinse buffer. Incorporated
Br-dUTP was detected after the addition of fluorescein-labelled
anti-bromodeoxyuridine antibody (5.0ml) and incubation for
30min at room temperature in darkness. Flow cytometric analysis
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software (Nippon Becton Dickinson, Tokyo, Japan).
Immunofluorescence analysis for FAP-1
After harvesting by scraping, 1 10
6 primarily cultured colon
cancer cells were washed with PBS and fixed with 1% formalde-
hyde for 15min on ice. Fixed cells were centrifuged, resuspended
in PBS and mixed 1:10 with ice-cold 70% ethanol to solubilise
membranes. Then, cells were incubated with 10mgml
 1 polyclonal
goat anti-human FAP-1 antibody (Santa Cruz Biotechnology) for
30min at 41C and washed in PBS. Fluorescein-conjugated anti-goat
IgG, as secondary antibody (Dako Corp., Carpinteria, CA), was
added to the cells for 30min at 41C. Cells were washed again in PBS
and the intensity of fluorescence was analysed with FACScan flow
cytometer and LYSIS II software (Nippon Becton Dickinson,
Tokyo, Japan). An isotype-matched control antibody was used to
determine nonspecific binding. A total of 10000 cells were
examined for each evaluation. Data were expressed as relative
fluorescence intensity (RFI¼mean fluorescence intensity of cells
stained with anti-FAP-1 Ab/mean fluorescence intensity of cells
stained with control Ab).
RT–PCR detection of FAP-1
RNA was isolated from primarily cultured colon cancer cells by
lysis in guanidine thiocyanate (Sigma Chemical Co, St Louis, MO,
USA) followed by phenol extraction and ethanol precipitation.
cDNA was synthesised from 2mg of total isolated RNA in a 20ml
reaction mixture containing 4mlo f5 RT reaction buffer, 10U of
Rnasin (Promega Corp., Madison, WI, USA), 200mM deoxynucleo-
tide triphosphate, 40pM oligodeoxythymidylic acid primer, and
20U of Moloney murine reverse transcriptase (Promega). The
mixture was incubated at 421C for 1h and then incubated at 531C
for 30min. The unhybridised RNA was then digested with 10U of
Rnase H at 371C for 10min.
PCR was performed on cDNA using primers (sense and
antisense) for the amplification of FAP-1 and a house-keeping
gene, b-actin. The primers were designed according to published
sequences: FAP-1, (sense) 50-AGGTCTGCAGAGAAGCAAGAATAC-
30 and (antisense) 50-GAATACGAGTGTCAGACATGG-30 (Irie et al,
2001); b-actin, (sense) 50-ACTACCTCATGAAGATCCTCA-30 and
(antisense) 50-CAGGAGGAGCAATGATCTTGA-30(Irie et al, 2001).
Thermal cycling was performed as follows: denaturation at 941C
for 1min, annealing at 551C for 1min, and extension at 721C for
1min. In all, 30 cycles were performed for the FAP-1 PCR and 28
cycles for the b-actin PCR. Primers were used at a final
concentration of 0.1mM each, dNTPs at 50mM, MgCl2 at 1.5mM,
Taq DNA polymerase at 1.0U per 50ml reaction. PCR products of
607 and 762bp were predicted for FAP-1 and b-actin, respectively.
PCR products were separated by electrophoresis in 2% agarose gels
and stained with ethidium bromide. The target bands were
analysed densitometrically by using a GS-700 Imaging Densit-
ometer (BioRad, Hercules, CA, USA). Fas-associated phosphatase-
1 cDNA was semiquantitated by densitometric comparison with b-
actin from the same sample.
Statistical analysis
All experiments for cell cultures were performed at least three
times. The results are described as mean7standard deviation.
Statistical analysis was performed by one-way analysis of variance
and comparisons among groups were performed by independent
sample t-test or Bonferroni’s multiple-comparison t-test. To
examine the correlation between the number of FasL-positive
TILs and the percentage of in situ apoptotic colon cancer cells, log
transformation was performed on the former data, which allowed
statistical analysis of a linear relationship between the two
variables by calculating the Pearson’s correlation coefficient. A
two-tailed P-value less than 0.05 was considered to be statistically
significant.
RESULTS
Immunohistochemical analysis of FAP-1, FasR, and FasL
The immunostaining with each antibody was judged to be
antibody specific by using the immunising peptide for each
antibody as an internal control. Inclusion of the soluble peptide
immunogen during immunohistochemistry resulted in direct
competitive displacement of positive staining in consecutive
control sections.
By immunohistology, FAP-1 was present in 20 out of 28 cases
(71.4%) of colon adenocarcinomas. Fas-associated phosphatase-1
was primarily localised in carcinoma cells, rather than in infiltrating
lymphocytes. Fas-associated phosphatase-1 was located primarily in
the cytoplasm and along the cell membrane, while nuclei were
clearly negative (Figure 1A). Fas-associated phosphatase-1-positive
cells were randomly distributed within a section. Intensity of
immunostaining varied from weak to intense in neoplastic areas,
both within individual tumours and among tumours, and was
independent of histological type and staging of the cancer.
In contrast, FasR was present in all colon adenocarcinomas
tested (Figure 1B). Extent and intensity of the staining did not vary
among different tumour staging or histological types, and did not
correlate to the percentage of TUNEL-positive tumour cells.
As demonstrated by CD45 immunohistochemical staining, all 28
carcinomas were infiltrated by immunocytes with lymphoid
morphology. In all cases of colon carcinomas, FasL immunostain-
ing was observed in tumour infiltrating lymphocytes (TILs) that
had been identified by CD45 staining in consecutive sections
(Figure 1C). The number of FasL-positive TILs observed under
high-power microscopy did not correlate with cancer staging or
differentiation. Tumour cells were FasL positive in 17 out of 28
(60.7%) colon carcinomas (not shown).
Apoptosis of colon cancer cells
TUNEL-positive cancer cells were randomly distributed in tumour
nests and were accompanied by morphological signs of apoptosis,
such as chromatin condensation, detachment of the cytoplasm
from the environment and formation of apoptotic bodies
(Figure 1D). TUNEL staining was also observed in TILs near or
distal to tumour nests.
In colon cancers with negative FAP-1 immunostaining (n¼8), a
linear correlation was observed between the percentage of
apoptotic cancer cells and the log value of Fas-positive cell counts
of TILs (r¼0.835, Po0.01; Figure 2A). In contrast, in FAP-1-
positive colon carcinomas (n¼20), no correlation was observed
between apoptosis of cancer cells and FasL expression in TILs
(Figure 2B). Additionally, the percentage of apoptotic cancer cells
was lower in colon cancers with positive FAP-1 immunostaining
than in FAP-1-negative tumours (4.071.2 vs 5.971.7; Po0.05).
However, apoptosis of colon cancer cells did not vary with tumour
stage or differentiation.
Fas-mediated apoptosis in primarily cultured cancer cells
To further evaluate the sensitivity of colon cancer cells to FasR-
mediated apoptosis, primarily cultured tumour cells from each
resected sample were individually treated with agonistic anti-Fas
MoAb CH-11. Purity of isolated cancer cells, as assessed by light
microscopy, electronic microscopy and immunohistochemistry for
keratin, was more than 97% in each case (not shown). After
incubation for 24h in the presence of CH-11 at concentrations of
up to 500ngml
 1, a dose-dependent increase of apoptotic cells was
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cancers without FAP-1 immunostaining (FasR-sensitive group)
(Figure 3A).
The percentage of cell death was elevated to 11.1974.04 at
10ngml
 1 of CH-11, which was significantly higher with control
antibody (Po0.05), and reached 27.6377.08 at a concentration of
500ngml
 1 of CH-11. However, higher doses of CH-11 (to
1000ngml
 1) did not result in a further increase of tumour cell
apoptosis (P40.05). In contrast, the percentage of apoptotic
tumour cells in the other 20 cases of colon cancers with FAP-1
immunostaining remained stable despite increasing CH-11 con-
centrations (FasR-refractory group). Even in the presence of
1000ngml
 1 CH-11, the percentage of apoptotic cancer cells in
this group was 3.8271.36, which was not significantly different
from treatment with control antibody (4.1271.53; P40.05).
FAP-1 expression levels in colon cancer cells
To confirm the difference of FAP-1 expression levels between the
FasR-sensitive and FasR-refractory group, we quantified protein
and mRNA expression of FAP-1 in cultured cancer cells by flow
cytometric immunofluorescence analysis and RT–PCR. As shown
by flow cytometric immunofluorescence analysis, FAP-1 protein
was strongly expressed by colon cancer cells of the FasR-refractory
group (n¼20; RFI¼38.6275.82), which showed positive immu-
nostaining with FAP-1 antibody in tissue sections (Figure 4A). In
contrast, only a limited amount of FAP-1 protein was detected in
tumour cells of the FasR-sensitive group (n¼8; RFI¼5.171.8),
which was significantly lower than that of the FasR-refractory
group (Po0.01) (Figure 4B). Similarly, FAP-1 mRNA was
abundantly expressed by tumour cells from the FasR-refractory
group, while a much weaker expression of FAP-1 mRNA was
observed in the Fas-sensitive group (Figure 5). Semiquantification
of RT–PCR results revealed that the relative amount of FAP-1
mRNA in the Fas-refractory group (n¼20; 1.8270.63) was
significantly higher than in the Fas-sensitive group (n¼8;
0.3770.19) (Po0.01).
Inhibition of FasR resistance by Ac-SLV
To further investigate whether FAP-1 expression did contribute to
the FasR refractory property of colon cancer cells, we blocked the
interaction between FAP-1 and FasR. Before treatment with CH-11
mAb, cultured tumour cells were preincubated with Ac-SLV. Ac-
SLV has the same amino-acid sequence as the C-terminal end of
FasR. Thus, Ac-SLV competes with FasR for the binding to FAP-1
Figure 1 Immunohistochemical examination of FAP-1, FasR and FasL expression and TUNEL staining in human colon adenocarcinomas. Antibodies were
detected using a DAB method that produces a brown colour. Counterstaining of nuclei with haematoxylin (blue). (A) FAP-1-positive immunohistochemical
staining in the cytoplasm of colon adenocarcinoma cells. (B) FasR-positive immunohistochemical staining in the cytoplasm of colon adenocarcinoma cells.
(C) FasL-positive immunohistochemical staining in the cytoplasm of TILs. (D) TUNEL staining in apoptotic colon adenocarcinoma cells. Only those cells with
positive TUNEL staining and exhibiting apoptotic morphology were considered apoptotic.
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FasR sensitivity of colon cancer cells in the FasR-refractory group.
It also increased the number of apoptotic tumour cells after
incubation with CH-11 in a dose-dependent manner (Figure 3B).
The percentage of apoptotic cancer cells from the FasR-refractory
group pretreated with Ac-SLV was 9.9173.83 in the presence of
10ngml
 1 CH-11, which was significantly higher than in controls
(Po0.05), and reached 26.7278.2 when the concentration of CH-
11 was increased to 500ngml
 1. However, a concentration of
1000ngml
 1 of CH-11 did not increase in apoptosis of colon
cancer cells any further (P40.05).
On the other hand, treatment with Ac-SLV alone did not
increase the apoptosis of colon cancer cells (Figure 3B).
Furthermore, preincubation with Ac-SLV did not affect the
apoptosis of colon cancer cells from the FasR-sensitive group
significantly in the presence of CH-11 at different concentrations
(data not shown).
DISCUSSION
The present study demonstrated a high incidence of FAP-1
expression (71%) in colon carcinomas in the presence of Fas
receptors. Moreover, FAP-1-expressing colon cancer cells were
refractory to FasR-mediated apoptosis. This resistance could be
reversed by blockade of FAP-1 and FasR interaction with an
interacting tripeptide Ac-SLV.
It has been demonstrated in vitro and in vivo that colon cancer
cells coexpress Fas receptors and functional FasLs on their cell
surface (Houghton et al, 1997; Ding et al, 1998; Krammer et al,
1998; O’Connell et al, 1998; Peduto et al, 1999; Yoong et al, 1999;
Vermijlen et al, 2001). Thus, it was not surprising that Fas receptor
was expressed in all cases of colon carcinomas to some extent.
Approximately 61% of colon cancers coexpressed FasL. A recent
study has also reinforced the notion that colon cancers are
resistant to FAS-mediated apoptosis (Houston et al, 2003).
Furthermore, like in other malignancies (O’Connell et al, 1999;
Fukuzawa et al, 2001; Meech et al, 2001), FasL-positive TILs were
found in all cases of colon cancer in our study, which probably
represented the local immune response of hosts against tumours.
As activated CTLs and NK cells can express FasL and induce
apoptosis in Fas-bearing cells, it is unclear as to why Fas-bearing
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Figure 2 Correlation between the percentage of in situ apoptotic colon
adenocarcinoma cells and the number of FasL-positive TILs. (A) In FAP-1-
negative colon cancers, a linear correlation was observed between the
percentage of apoptotic tumour cells and the log value of FasL-positive TIL
counts (r¼0.835, Po0.01). (B) In FAP-1-positive colon cancers, the
percentage of apoptotic tumour cells was not correlated to FasL-positive
TIL counts.
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Figure 3 Percentage of apoptotic cultured colon cancer cells in the
presence of different concentrations of CH-11. (A) When the concentra-
tion of CH-11 increased up to 500ngml
 1, a dose-dependent increase of
the apoptotic percentage of cultured colon cancer cells was observed in
those cases without FAP-1 expression (&, Fas-sensitive group; n¼8,
Po0.05), while the ones in the cases with FAP-1 expression (’, Fas-
refractory group; n¼20) remained stable (P40.05). However, further
elevation of CH-11 concentration from 500 to 1000ngml
 1 did not result
in a further increment of tumour cell apoptosis in Fas-sensitive group
(P40.05). (B) After preincubation with Ac-SLV, cultured colon cancer cells
of Fas-refractory group showed a dose-dependent increase of the
apoptotic percentage with the increase of CH-11 concentration up to
500ngml
 1 (’)( Po0.05) in contrast to untreated ones (&). Further
elevation of CH-11 concentration from 500 to 1000ngml
 1 did not result
in a further increment of tumour cell apoptosis (P40.05). Ac-SLV alone did
not increase apoptosis of tumour cells when treated with control antibody
(P40.05).
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why colon cancer cells do not undergo apoptosis via Fas and FasL
interaction.
Presently, the exact mechanisms by which colon cancer cells
escape from FasL-induced apoptosis are not fully understood.
Some authors hypothesised that colon cancer cells are resistant to
FasR-mediated apoptosis due to the presence of inhibitory
proteins in the Fas signal transduction pathway (Ding et al,
1998; Krammer et al, 1998; O’Connell et al, 1998; Yoong et al, 1999;
Vermijlen et al, 2001). A possible candidate is FAP-1 because
activation and dysregulation of the FAP-1 promoter has been
demonstrated in human colon carcinoma cell line in vitro (Irie
et al, 2001). We examined this hypothesis by investigating the role
of FAP-1 as an inhibitor in FasR-mediated apoptosis of colon
cancer cells.
Using immunohistochemistry, we demonstrated FAP-1 expres-
sion in more than 70% of colon cancers, concurring with the
immunohistochemical localisation of FAP-1 in a large panel of
cancers of various origins, including colon, lung, and breast
carcinomas, reported by Lee et al (1999b). Additionally, FAP-1
immunostaining, herein, was observed along the cell membrane
and/or in the cytosol, suggesting a possible role for FAP-1 to
interact with the cytosolic domain of Fas just beneath the cell
membrane (Ungefroren et al, 1999). This hypothesis was further
supported by the present findings that colon cancers with FAP-1
expression had fewer apoptotic tumour cells in comparison to the
ones without such expression. Furthermore, in colon cancers with
FAP-1 expression, the percentage of apoptotic colon cancer cells,
which bore FasR on their surface, did not correlate with the
number of FasL-positive TILs surrounding the tumour nests. In
contrast, the percentage of apoptotic colon cancer cells in tissue
sections revealed a positive correlation with the FasL-positive TIL
counts. The correlation was more pronounced when the level of
FasL-positive TIL counts was in the lower range. This suggests that
the sensitivity of colon cancer cells to FasR-mediated apoptosis
depends on in vivo FAP-1 expression. In vivo expression of FAP-1
was also suggested to be a possible mechanism for Fas resistance in
human hepatoblastomas by Lee et al (1999b).
Although FAP-1 has been suggested to interact with the
‘suppressive domain’ of Fas receptor that is involved in the
inhibition of the apoptotic signal (Ungefroren et al, 2001), no
direct proofs exists for the contribution of FAP-1 expression to
FasR resistance in colon cancer cells. Hence, we performed
primary cultures of colon cancer cells on our samples, and treated
them with CH11, an agonistic Fas mAb, in order to demonstrate
directly the influence of FAP-1 expression on FasR sensitivity. In
consistence with our in vivo evaluation, our data demonstrated a
dose-dependent increase in the amount of apoptosis induced by
CH-11 in colon cancer cells in parallel to a reduced expression of
FAP-1 mRNA and protein.
On the other hand, despite exposure to a high dose of CH-11
(1000ngml
 1), colon cancer cells, which had pronounced FAP-1
expression at mRNA and protein levels, were irresponsive to FasR-
mediated apoptosis. These data are in line with a recent finding on
a pancreatic cancer cell line, showing that FAP-1-expressing
pancreatic cancer cells were resistant to Fas-mediated apoptosis
(Ungefroren et al, 1999).
Furthermore, treatment with Ac-SLV tripeptide abrogated the
resistance of Fas-mediated apoptosis in FAP-1-expressing colon
cancer cells, as apoptosis was induced in these cells by CH-11 in a
1 2 3 4 5 6 7 8 9 10 11 12 13 14 Patient no.
FAP-1
-actin
15 16 17 18 19 20 21 22 23 24 25 26 27 28 Patient no.
FAP-1
-actin
Figure 5 RT–PCR analysis of FAP-1 mRNA expression in cultured
colon cancer cells. Patients no. 1, 3, 6, 13, 16, 20, 21, and 24 belonged to
the Fas-sensitive group (sensitive to CH11-induced apoptosis; n¼8), while
the rest belonged to Fas-refractory group (resistant to CH11-induced
apoptosis; n¼20). 0
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Figure 4 Flow cytometric analysis of FAP-1 expression on cultured
colon cancer cells of Fas-refractory group (A) and Fas-sensitive group (B)
using polyclonal anti-FAP-1 antibody (bold peaks) or an irrelevant antibody
(isotype control) for the determination of background staining (thin-line
peaks).
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amino acids (SLV) with FasR. This sequence is necessary and
sufficient to interact with FAP-1 (Moulian et al, 1999). Thus, Ac-
SLV can competitively prevent the interaction of FAP-1 with Fas
and results in the induction of Fas-mediated apoptosis (Yanagi-
sawa et al, 1997; Sawa et al, 1999). Similarly, application of Ac-SLV
in thyroid follicular cells has also been found to enhance Fas-
mediated apoptosis (Myc et al, 1999). In this context, the present
inhibition of Ac-SLV of FasR resistance in colon cancer cells
substantiates our hypothesis that FAP-1 is an inhibitor of Fas-
mediated apoptosis in colon cancer cells.
Interestingly, in colon cancers without FAP-1 expression, the
percentage of apoptotic tumour cells was positively correlated to
the logarithmic value of FasL-positive TIL count.
Likewise, even when the interaction between FasR and FAP-1
was blocked, agonistic anti-Fas mAb enhanced apoptosis in
primarily cultured tumour cells in a dose-dependent manner up
to a concentration of 500ngml
 1. This suggests that, in addition to
FAP-1 expression, there are other factors in the Fas signalling
pathway that can influence celluar sensitivity to Fas-mediated
apoptosis in colon cancer cells, for example, reduction of Fas
receptor levels on colon cancer cells (Butler et al, 2000; Song et al,
2001b), release of soluble Fas (Cheng et al, 1994) or decoy receptor
(Pitti et al, 1998) for FasL that blocks FasL on CTLs, mutation or
modification of an essential signalling molecule of the Fas
signaling pathway (Itoh and Nagata, 1993), and increased
expression of BCL-2 gene (Meterissian and Kontogiannea, 1996).
Hence, further studies are needed to elucidate the complete
pathway of Fas signaling processes in generating apoptotic
responses in colon carcinomas.
In conclusion, the present study suggests that FAP-1 expression
contributes to the resistance of colon cancer cells to Fas-mediated
apoptosis and, thus, is involved in immune escape from CTLs and
NK cells. These effects may be abolished by a blockade of the
interaction of FAP-1 with FasR.
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